BioCentury | Feb 23, 2021
Management Tracks

Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana

...By BioCentury Staff Kite Pharma veteran Ken Takeshita will join Daiichi Sankyo Co. Ltd. (Tokyo:4568) as global head of...
BioCentury | Feb 10, 2021
Finance

Notch’s $85M series A builds on Allogene deal for off-the-shelf, iPSC-derived cell therapies

...undisclosed firm.Chang and other Allogene executives were among the management team at cell therapy pioneer Kite Pharma...
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...chair, Julie McHugh, will become executive chair.Frank Neumann has joined Gilead Sciences Inc. (NASDAQ:GILD) unit Kite Pharma...
...Pharmaceuticals Inc. [MERGED] Editas Medicine Gilead Sciences Inc. Editas Medicine Inc. Ironwood Pharmaceuticals Inc. Vedanta Biosciences Inc. Primmune Therapeutics Inc. Vedanta Primmune Therapeutics Werewolf Therapeutics Kite Pharma Gilead Ironwood Editas...
BioCentury | Jan 27, 2021
Finance

Pontifax’s largest-ever fund, at $404M, will help firm maintain stakes in growth-stage portfolio companies

...companies, so we need more reserves.”  Standout venture deals include investments in cancer cell therapy companies Kite Pharma...
BioCentury | Jan 27, 2021
Management Tracks

Novartis’ chief digital officer stepping down; plus moves at Taysha, Roivant, Faze and more

...to SVP, preclinical and translational science. Bond was most recently VP of cellular engineering at Kite Pharma. Karuna...
BioCentury | Jan 23, 2021
Emerging Company Profile

ONK’s CAR NK cells hit the TRAIL

...million in venture funding and brought on CEO Chris Nowers, formerly head of Europe at Kite Pharma...
BioCentury | Jan 20, 2021
Management Tracks

Marincola to lead Kite’s cell therapy research; plus moves at T-knife, Applied Molecular Transport, Frequency and NexImmune

...By Danielle Golovin, Staff Writer Kite Pharma Inc. hired Francesco Marincola as SVP and global head of cell...
...officer at UnitedHealth Group Inc. (NYSE:UNH), to its board. Before NexImmune, Knight led Kite’s Yescarta axicabtagene ciloleucel clinical program. BC Staff Kite Pharma...
BioCentury | Jan 9, 2021
Finance

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

...Ventures, whose team includes several former members of Kite Pharma...
...Arie Belldegrun and David Chang, who led Kite Pharma...
BioCentury | Jan 7, 2021
Deals

Jan. 6 Quick Takes:  Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

...role in validating COVID-19 serology tests. BC Staff Ribometrix Genentech Pfizer Dewpoint Therapeutics Kite Pharma Gilead Oxford...
BioCentury | Jan 6, 2021
Emerging Company Profile

Kite, Forty Seven vets on board for launch of oncolytic virus start-up IconOVir with $77M series A

...the start-up’s investment team. Among them were Arie Belldegrun, the former chairman, president and CEO of Kite Pharma...
Items per page:
1 - 10 of 415
BioCentury | Feb 23, 2021
Management Tracks

Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana

...By BioCentury Staff Kite Pharma veteran Ken Takeshita will join Daiichi Sankyo Co. Ltd. (Tokyo:4568) as global head of...
BioCentury | Feb 10, 2021
Finance

Notch’s $85M series A builds on Allogene deal for off-the-shelf, iPSC-derived cell therapies

...undisclosed firm.Chang and other Allogene executives were among the management team at cell therapy pioneer Kite Pharma...
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...chair, Julie McHugh, will become executive chair.Frank Neumann has joined Gilead Sciences Inc. (NASDAQ:GILD) unit Kite Pharma...
...Pharmaceuticals Inc. [MERGED] Editas Medicine Gilead Sciences Inc. Editas Medicine Inc. Ironwood Pharmaceuticals Inc. Vedanta Biosciences Inc. Primmune Therapeutics Inc. Vedanta Primmune Therapeutics Werewolf Therapeutics Kite Pharma Gilead Ironwood Editas...
BioCentury | Jan 27, 2021
Finance

Pontifax’s largest-ever fund, at $404M, will help firm maintain stakes in growth-stage portfolio companies

...companies, so we need more reserves.”  Standout venture deals include investments in cancer cell therapy companies Kite Pharma...
BioCentury | Jan 27, 2021
Management Tracks

Novartis’ chief digital officer stepping down; plus moves at Taysha, Roivant, Faze and more

...to SVP, preclinical and translational science. Bond was most recently VP of cellular engineering at Kite Pharma. Karuna...
BioCentury | Jan 23, 2021
Emerging Company Profile

ONK’s CAR NK cells hit the TRAIL

...million in venture funding and brought on CEO Chris Nowers, formerly head of Europe at Kite Pharma...
BioCentury | Jan 20, 2021
Management Tracks

Marincola to lead Kite’s cell therapy research; plus moves at T-knife, Applied Molecular Transport, Frequency and NexImmune

...By Danielle Golovin, Staff Writer Kite Pharma Inc. hired Francesco Marincola as SVP and global head of cell...
...officer at UnitedHealth Group Inc. (NYSE:UNH), to its board. Before NexImmune, Knight led Kite’s Yescarta axicabtagene ciloleucel clinical program. BC Staff Kite Pharma...
BioCentury | Jan 9, 2021
Finance

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

...Ventures, whose team includes several former members of Kite Pharma...
...Arie Belldegrun and David Chang, who led Kite Pharma...
BioCentury | Jan 7, 2021
Deals

Jan. 6 Quick Takes:  Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

...role in validating COVID-19 serology tests. BC Staff Ribometrix Genentech Pfizer Dewpoint Therapeutics Kite Pharma Gilead Oxford...
BioCentury | Jan 6, 2021
Emerging Company Profile

Kite, Forty Seven vets on board for launch of oncolytic virus start-up IconOVir with $77M series A

...the start-up’s investment team. Among them were Arie Belldegrun, the former chairman, president and CEO of Kite Pharma...
Items per page:
1 - 10 of 415